GeoVax Labs postpones proposed public offering

NewsGuard 100/100 Score
Jul 1 2010

GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone its proposed public offering of units, each consisting of a share of common stock and a warrant to purchase another share.

"Due to unfavorable market conditions, our board has determined it is in the best interest of our stockholders to postpone the offering,'' said Robert McNally, PhD, President and CEO.  "We intend to consult with our advisors and re-evaluate the size and structure of our proposed offering."

SOURCE GeoVax Labs, Inc.

Posted in:

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

Milestone in diabetes treatment: Transgenic cow produces human insulin in milk
Study reveals association between ribosomal DNA copy number and disease risk
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy
Nuclera eProtein Discovery system installed at leading academic institutes
From farm to pharmacy: Transgenic cow milk as a new source of human insulin
Sphere Fluidics appoints Dale Levitzke as Chief Executive Officer
Insilico Medicine's AI-designed drug ISM3412 receives FDA IND approval
New study to test novel psychedelic compound as potential treatment for alcohol use disorder

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
AI-driven model identifies potent cancer-killing immune cells for personalized immunotherapy